PhysioGenix’s Substantial Growth in 2010 Expected to Continue in 2011

PhysioGenix experienced a tremendous year through the completion of a new research facility, addition of capabilities and record high sales. Milwaukee, WI (PRWEB) March 23, 2011 -- PhysioGenix, already a leader in customer focused contract research, expanded their research facilities, capabilities and research models in 2010. “We experienced tremendous growth in 2010 and anticipate additional growth in 2011,” stated PhysioGenix’s Director of Sales Darin Evans. PhysioGenix was a...

FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

FREMONT, Calif., Feb. 16 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients. Quark has completed enrollment and dosing in the dose-escalation safety portion (Part A) of a Phase 1/2 study and has...

Research points to potential treatment for kidney disease

Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought. The results are published in the current online issue of the Journal of the American Society of...

Abnormal blood calcium levels deadly for kidney disease patients

Abnormally high or low blood calcium levels are linked to an increased chance of premature death in non-dialysis kidney disease patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate the potential importance of finding drugs or other treatments that maintain normal blood calcium levels in non-dialysis...

Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing. This followed review of available safety data from two clinical trials for Quark's siRNA QPI-1002, at doses up to 10 mg/kg, the highest evaluated to date. QPI-1002 is designed to temporarily inhibit expression of the stress-response gene,...

AngioDynamics introduces new family of micro-introducer kits with stiffened introducer option

AngioDynamics today announced the launch of a new family of micro-introducer kits, featuring a stiffened introducer...

Kidney drug plan divides transplant and dialysis supporters

The New York Times: "A Congressional proposal to help pay for drugs needed by transplant recipients to prevent rejection of donated kidneys has run into opposition from dialysis providers, drug companies and the National Kidney Foundation." The groups support extending Medicare drug coverage but say the measure would cut funding for...

26 Operations, 13 Kidneys: Hope To Few With Little – CBS 4

CBS 4"You are going to die a lot earlier sitting on that dialysis machine than if you get transplanted," says Melancon, whose goal is to pair domino kidney... read...

Wrong Blood Thinners for Dialysis Patients Often Given: Study – AboutLawsuits.com

AboutLawsuits.comA new study indicates that about 20% of dialysis patients are given blood thinners after angioplasty that could increase their risk of bleeding or death,... read...

Misuse Of Blood Thinners In Dialysis Patients Reported – Medical News Today (press release)

Medical News Today (press release)The two drugs "are not recommended for use in kidney dialysis patients" (Wilson, 12/8). US News and World Report/healthday: "According to [study author Dr.... read...